MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3324/haematol.2025.288770

Медицинская библиотека · Haematologica · 2026

GvHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.

Stölzel Friedrich, Stelljes Matthias, Beelen Dietrich Wilhelm, Markiewicz Miroslaw, Reményi Péter, Luft Thomas, Ciceri Fabio, Wagner-Drouet Eva-Maria, Junghanss Christian, Scheid Christoph, Patriarca Francesca, Socié Gerard, Hilgendorf Inken, Rambaldi Alessandro, Schaefer-Eckart Kerstin, Russo Domenico, Wulf Gerald, Glass Bertram, Labussiere-Wallet Hélène, Stuhler Gernot, Bieniaszewska Maria, Casper Jochen, Holler Ernst, Benedetti Fabio, Iori Anna Paola, Kunadt Desiree, Mihajlović Jelena, Schild Bettina, Khan Imran, Li Xieran, Bethge Wolfgang

СтатьяКлиническое исследование III фазыРандомизированное исследованиеПеревод в очереди

Аннотация

Acute myeloid leukemia (AML) is the most common indication for allogeneic hematopoietic cell transplantation (alloHCT), yet graft-versus-host disease (GvHD) remains a major post-transplant complication. Conditioning regimens, particularly reduced-intensity approaches, are critical in optimizing outcomes. This subgroup analysis of the phase III MC-FludT.14/L trial compared treosulfan-fludarabine with reduced-intensity busulfan-fludarabine in 352 AML patients (aged 31-70 years) undergoing alloHCT. The primary endpoint was 24-month event-free survival; secondary endpoints included overall survival, GvHD incidence, relapse/progression, and non-relapse mortality. Treosulfan compared to busulfan demonstrated superiority: 24-month event-free survival was 65% vs. 53% (P=0.01), and overall survival was 73% vs. 65%. Event-free survival benefits were consistent across AML risk categories and notably higher in patients with Hematopoietic Cell Transplantation Comorbidity Index score >2 (62% vs. 42%, P=0.02). Treosulfan also showed lower non-relapse mortality and relapse rates. GvHD outcomes favored treosulfan, with a significantly lower incidence of extensive chronic GvHD at 24 months (15.1% vs. 28.1%, P=0.01). GvHD-free and relapse-free survival was also improved (53% vs. 40%, P=0.02). The safety profile was more favorable with treosulfan. These findings support treosulfan-fludarabine as a more effective and safer conditioning regimen than busulfan-fludarabine for AML patients undergoing alloHCT, particularly those at higher risk.

Для цитирования: Stölzel Friedrich, Stelljes Matthias, Beelen Dietrich Wilhelm, Markiewicz Miroslaw, Reményi Péter, Luft Thomas, Ciceri Fabio, Wagner-Drouet Eva-Maria, Junghanss Christian, Scheid Christoph, Patriarca Francesca, Socié Gerard, Hilgendorf Inken, Rambaldi Alessandro, Schaefer-Eckart Kerstin, Russo Domenico, Wulf Gerald, Glass Bertram, Labussiere-Wallet Hélène, Stuhler Gernot, Bieniaszewska Maria, Casper Jochen, Holler Ernst, Benedetti Fabio, Iori Anna Paola, Kunadt Desiree, Mihajlović Jelena, Schild Bettina, Khan Imran, Li Xieran, Bethge Wolfgang. GvHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial.. Haematologica. 2026. DOI: 10.3324/haematol.2025.288770.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.